View Future GrowthALR Technologies SG 과거 순이익 실적과거 기준 점검 0/6ALR Technologies SG 의 수입은 연평균 -24.4%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 15.3%의 비율로 증가했습니다. 매출은 연평균 11.1%의 비율로 증가해 왔습니다.핵심 정보-24.44%순이익 성장률-17.74%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률11.14%자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.공시 • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.공시 • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.공시 • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.공시 • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.공시 • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.매출 및 비용 세부 내역ALR Technologies SG가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:ALRT.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-222130 Sep 250-212130 Jun 250-212131 Mar 250-182131 Dec 240-163130 Sep 240-133130 Jun 240-104131 Mar 240-94131 Dec 230-73130 Jun 230-114131 Mar 230-114131 Dec 220-114030 Jun 220-83131 Mar 220-93131 Dec 210-82030 Sep 210-73030 Jun 210-72131 Mar 210-63131 Dec 200-62130 Sep 200-71230 Jun 200-61131 Mar 200-92231 Dec 190-92230 Sep 190-72230 Jun 190-62131 Mar 190-31031 Dec 180-42030 Sep 180-42130 Jun 180-42131 Mar 180-42131 Dec 170-31030 Sep 170-30030 Jun 170-100031 Mar 170-100131 Dec 160-100130 Sep 160-101130 Jun 160-31131 Mar 160-61131 Dec 150-61130 Sep 150-611양질의 수익: ALRT.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: ALRT.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ALRT.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 24.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ALRT.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ALRT.F은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ALRT.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/11 05:51종가2026/06/09 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ALR Technologies SG Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Juan NobleTaglich Brothers, Inc.
공시 • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.
공시 • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
공시 • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
공시 • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.
공시 • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.
공시 • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.